ReShape Lifesciences to Present at Dawson James 6th Annual Small Cap Growth Conference
ReShape Lifesciences (NASDAQ:RSLS) will be represented by Thomas Stankovich, Chief Financial Officer, at the 6th Annual Dawson James Small Cap Growth Conference on October 21, 2021. The event will take place at the Wyndham Grand Hotel in Jupiter, Florida, and Stankovich's presentation is slated for 2:25 p.m. ET. He will discuss the company's business operations and value creation in its weight-loss product portfolio. Interested investors can schedule one-on-one meetings through their Dawson James contact or Daniel Kontoh-Boateng at The Ruth Group.
- None.
- None.
SAN CLEMENTE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced Thomas Stankovich, Chief Financial Officer of the Company, will present at the Annual Small Cap Growth Conference hosted by Dawson James Securities on October 21, 2021, at the Wyndham Grand Hotel in Jupiter, Florida.
During Mr. Stankovich’s presentation, he will provide an overview of the Company’s business operations and highlight ongoing value creation efforts across ReShape’s commercial portfolio of weight-loss products and services.
Details of the presentation are below:
Event: 6th Annual Dawson James Small Cap Growth Conference
Date: Thursday, October 21, 2021
Time: 2:25 p.m. ET
Location: Track 1 – Preserve C
Investors participating in the conference who would like to schedule a one-on-one meeting with ReShape’s management may do so by contacting their Dawson James representative or Daniel Kontoh-Boateng of The Ruth Group at dboateng@theruthgroup.com.
An audio webcast of ReShape’s presentation will be available on the investor relations section of the Company’s website, ir.reshapelifesciences.com. Replays of the webcast will be available for 90 days after the date of the presentation.
ABOUT RESHAPE LIFESCIENCES INC.
ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals.
CONTACTS
ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com
Investor Contact:
Daniel Kontoh-Boateng
Assistant Vice President
The Ruth Group
646-536-7019
dboateng@theruthgroup.com
FAQ
When will ReShape Lifesciences present at the Dawson James Small Cap Growth Conference?
Who is presenting for ReShape Lifesciences at the conference?
Where is the Dawson James Small Cap Growth Conference being held?
What topics will be covered in the ReShape Lifesciences presentation?
How can investors schedule meetings with ReShape Lifesciences during the conference?
